Types of nucleic acid-based products under development by the pharma industry Viral vector delivery of nucleic acids Bacterial vector delivery of nucleic acids Non-viral vector delivery of nucleic acids Chemical Technologies Physical Technologies Current therapeutic applications for the viral and non-viral delivery of nucleic acids Leading nucleic acid-based products in development Future commercial applications & opportunities

STRATEGIES OF DRUG DELIVERY COMPANIES

Leading nucleic acid drug delivery companies Strategic developmental & commercialisation partnerships Mergers, acquisitions & joint ventures Intellectual Property

THE VIRAL AND NON-VIRAL VECTOR DELIVERY MARKET

Now 2009: Approved nucleic acid product sales Future 2018: Novel nucleic acid product sales and Global nucleic acid product sales

COMPETITOR ANALYSIS

Detailed analysis of leading companies covering:

Proprietary delivery technology Applications in the pharma industry Management/technical expertise Competition within the delivery technology sector Products in development/approved utilising the delivery technology Sales forecasts of products utilising the delivery technology Competitor ratio analysis

Companies analysed

Alnylam Pharmaceuticals, Inc. AlphaVax, Inc. Altea Therapeutics, Inc. AP Pharma, Inc. ArmaGen Technologies, Inc. BioDelivery Sciences International, Inc. Calando Pharmaceuticals, Inc. Cequent Pharmaceuticals, Inc. Copernicus Therapeutics, Inc. Diatos SA, Inc. DOR BioPharma, Inc Expression Genetics, Inc Inovio Biomedical Corporation MaxCyte, Inc Nanotherapeutics, Inc. NeoPharm, Inc. Novagali Pharma, S.A. Oxford Biomedica, Plc. PCI Biotech ASA. Silence Therapeutics, Plc. Targeted Genetics Corporation TissueGene, Inc. Vical, Inc. Zosano Pharma, Inc.

APPENDICIES

Source: Espicom Business Intelligence Ltd